Germany’s landmark compassionate use program for psilocybin: A new wave for psychedelic medicine in Europe

The Open Foundation reports: “In a bold move for European mental health care, Germany has become the first country in the EU to approve psilocybin therapy for patients with treatment-resistant depression outside of clinical trials! This decision, made under a compassionate use framework, marks a significant step forward in the responsible integration of psychedelic-assisted therapies into mainstream medicine … One of the most innovative aspects of Germany’s program is its decentralized decision-making process. Unlike similar schemes in Switzerland and Canada, where each patient requires regulatory approval, Germany empowers licensed psychiatrists at the participating sites to determine eligibility. This streamlines access and reduces bureaucratic delays, while maintaining high medical and ethical standards.”

For more psychedelic news and research, visit the psychedelic health professional network homepage.